The purpose of this study is to evaluate an experimental drug called treprostinil palmitil inhalation powder (TPIP) for the treatment of pulmonary arterial hypertension (PAH). The study aims to determine the safety, tolerability, and effectiveness of TPIP in PAH patients. Specifically, researchers want to know how safe it is to take TPIP for a long period of time, as well as learn more about how the drug works in the human body and the substances it produces (biomarkers). The study will also measure the amount of TPIP in the body (pharmacokinetics) and examine how the body reacts to the drug. Study procedures also include laboratory blood testing, a 6-minute walk test, and electrocardiogram (ECG).
What is the full name of this clinical trial?
An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term use of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension